

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2008 (24.12.2008)

PCT

(10) International Publication Number
WO 2008/155363 A3

(51) International Patent Classification:
C07K 14/705 (2006.01)

(21) International Application Number:
PCT/EP2008/057729

(22) International Filing Date: 18 June 2008 (18.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07301124.9 18 June 2007 (18.06.2007) EP

(71) Applicant (for all designated States except US): **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)** [FR/FR]; 101, rue de Tolbiac, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BENSUSSAN, Armand** [FR/FR]; 16, rue Auguste Lançon, F-75013 Paris (FR). **MARIE CARDINE, Anne** [FR/FR]; 3, rue Moulin Berson, F-94000 Creteil (FR).

(74) Agent: **WARCOIN, AHNER, TEXIER, LE FORESTIER, CALLON DE LAMARCK, COLLIN, TETAZ-Cabinet Regimbeau**; 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
19 February 2009

(54) Title: IDENTIFICATION OF NEW ISOFORMS OF THE MHC-CLASS I SPECIFIC RECEPTOR CD160 AND USES THEREOF

(57) Abstract: The present invention concerns an isolated polypeptide comprising a sequence selected in the group comprising SEQ ID NO.7, its orthologs, and derivatives thereof; a polynucleotide comprising a nucleic acid sequence encoding for said polypeptide; a vector comprising said polynucleotide; a host cell genetically engineered with said polynucleotide or with said vector; a pharmaceutical composition comprising said polypeptide, a polynucleotide coding for said polypeptide or a vector comprising said polynucleotide, and optionally a pharmaceutically acceptable carrier; a method for screening for antagonists and/or agonists of said polypeptide; and uses of said polypeptide, a polynucleotide coding for said polypeptide or a vector comprising said polynucleotide, for the manufacture of a medicament.



WO 2008/155363 A3

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/057729

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EPO Proteins [Online] 23 August 2004 (2004-08-23), "Sequence 3575 from Patent EP1447413." XP002507304 retrieved from EBI accession no. EPOP:CQ853106 Database accession no. CQ853106 the whole document & EP 1 447 413 A (RES ASS FORBIOTECHNOLOGY [JP] RES ASS FOR [JP]) 18 August 2004 (2004-08-18) paragraph [0060]; claims ----- -/--	1-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

9 December 2008

Date of mailing of the international search report

29/12/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040.
Fax: (+31-70) 340-3016

Authorized officer

Sommer, Birgit

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/057729

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] 23 August 2004 (2004-08-23), "Sequence 1619 from Patent EP1447413." XP002507305 retrieved from EBI accession no. EMBL:CQ851150 Database accession no. CQ851150 the whole document & EP 1 447 413 A (RES ASS FORBIOTECHNOLOGY [JP] RES ASS FOR [JP]) 18 August 2004 (2004-08-18) paragraph [0060]; claims	1-13
X	WO 2004/029218 A (INCYTE CORP [US]; MARQUIS JOSEPH P [US]; TRAN UYEN K [US]; LEE SOO YEU) 8 April 2004 (2004-04-08) claims; tables 2,3; sequence 16	1-13
X	WO 98/21240 A (DANA FARBER CANCER INST INC [US]; FREEMAN GORDAN J [US]; ANUMANTHAN AN) 22 May 1998 (1998-05-22) claims; figure 2; examples; sequences	1-3,6, 8-13
X	GIUSTINIANI J ET AL: "A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity" JOURNAL OF IMMUNOLOGY, vol. 178, no. 3, February 2007 (2007-02), pages 1293-1300, XP002453508 ISSN: 0022-1767 abstract; materials and methods;	1-3,6, 8-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2008/057729

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 3 (completely), 1, 2, 4-13 (all partially)

an isolated polypeptide comprising SEQ ID No. 7, wherein said polypeptide comprises SEQ ID No. 1 (i.e. CD160-TM) as well as subject-matter related thereto;

2. claims: 1, 2, 4-6, 8-13 (all partially)

an isolated polypeptide comprising SEQ ID No. 7, wherein said polypeptide comprises SEQ ID No. 19 (i.e. CD160 delta Ig-TM), as well as subject-matter related thereto;

3. claims: 1, 6-13 (all partially)

an isolated polypeptide comprising a derivative of SEQ ID No. 7 wherein said derivative is encoded by a polynucleotide comprising SEQ ID No. 18 (i.e. CD160 delta Ig-GPI), as well as subject-matter related thereto;

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/057729

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1447413	A	18-08-2004	NONE	
WO 2004029218	A	08-04-2004	AU 2003272799 A1	19-04-2004
WO 9821240	A	22-05-1998	AU 5253898 A	03-06-1998